Drug eluting coatings that can direct the host tissue response to implanted medical devices
have the potential to ameliorate both the medical and financial burden of complications from …

A promising strategy to accelerate joint implant integration and reduce recovery time and
failure rates is to deliver a combination of certain growth factors to the integration site. There is …

Exposure to the EGFR (epidermal growth factor receptor) inhibitor erlotinib promotes the
dynamic rewiring of apoptotic pathways, which sensitizes cells within a specific period to …

The use of microneedles has facilitated the painless localized delivery of drugs across the
skin. However, their efficacy has been limited by slow diffusion of molecules and often …

Traumatic wounds and congenital defects that require large-scale bone tissue repair have
few successful clinical therapies, particularly for craniomaxillofacial defects. Although …

Mesenchymal stem cell (MSC) therapies demonstrate particular promise in ameliorating
diseases of immune dysregulation but are hampered by short in vivo cell persistence and …

The functional success of a biomedical implant critically depends on its stable bonding with
the host tissue. Aseptic implant loosening accounts for more than half of all joint replacement …

Fibroblast growth factor 2 (FGF-2) is a potent mediator of stem cell differentiation and proliferation.
Although FGF-2 has a well-established role in promoting bone tissue formation, flaws …

The ability to control the timing and order of release of different therapeutic drugs will play a
pivotal role in improving patient care and simplifying treatment regimes in the clinic. The …

About 10% of total hip prostheses need revision within a decade after surgery due to mechanical
aseptic loosening of the implant, and the number of revisions is expected to rise due to …